UK Supreme Court rules in Lilly's favour on Alimta vitamin regimen patents

Actavis's products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain.

In June of 2015, the UK Court of Appeal ruled the Alimta vitamin regimen patent would be indirectly infringed when the generic product is reconstituted or diluted in saline, but not directly infringed under the doctrine of equivalents. Following this decision, Actavis launched pemetrexed Armisarte, previously Pemetrexed Actavis, at risk. Today's announcement (7 July 2017) by the UK Supreme Court finds the Actavis product infringing, regardless of the diluent used in reconstitution or dilution.

"While we do not yet know the court's reasoning, we are pleased with the UK Supreme Court's key conclusions that confirm the Alimta vitamin regimen patent would be infringed by these generic pemetrexed products in the UK, France, Italy and Spain prior to June 2021," said Michael J. Harrington, senior vice president and general counsel for Lilly.

Harrington continued: "We continue to emphasize that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. Intellectual property rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."